Edgewise Therapeutics is a biotechnology company focused on developing innovative therapies for rare muscle disorders such as Duchenne, Becker, and Limb Girdle muscular dystrophies, as well as McArdle disease. Utilizing a proprietary drug discovery platform, the company aims to create a holistic therapeutic approach to protect muscle health. Edgewise Therapeutics serves patients and families affected by these progressive muscle disorders, operating within the niche market of precision medicine for rare diseases. The business model involves retaining global development and commercialization rights to its programs, allowing for strategic collaborations and asset acquisitions to accelerate development and expand its pipeline. Revenue is generated through the development and commercialization of its lead molecule, sevasemten (EDG 5506), which targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers without affecting other muscle types.

Keywords: biotechnology, rare muscle disorders, Duchenne, Becker, Limb Girdle, McArdle disease, precision medicine, drug discovery, sevasemten, myosin, muscle health.